YHLO COVID-19 Rapid Antigen Test Kit (NP/NS) was recently granted official approval by the German Paul-Ehrlich-Institut (PEI)!
Congratulations!
COVID-19 Rapid Antigen Test Kit (NP/NS) was recently granted official approval by the German Paul-Ehrlich-Institut (PEI)!
Early besides from Germany, the performance of YHLO’s GLINE-2019-nCoV Ag assay has already been validated by different governments, such as ANSM from France, DHSC from the UK, MOH from the Italy, SEI from Spain, etc.
Basing on the combined evaluation reports, we are confident to declare that GLINE-2019-nCoV Ag Test is eligible to detect 4 Variants of Concerns, including Alpha (VOC1 Kent, UK, B.1.1.7), Beta (VOC2 South Africa, B.1.351), Gamma (VOC3 Brazil, P1), and Delta (VOC4 India, B.1.617.2 ) showing no drop off in sensitivity.
YHLO always strives to provide accurate and efficient immunoassays to better help the global to fight against COVID-19.
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
